# Endocyte clinical trials: 29 on ClinicalTrials.gov (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 29 trials with Endocyte as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Endocyte: 29 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/endocyte

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 29
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 29, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2020 | NCT04597411 | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | Endocyte | Phase 1 | Active not recruiting | Prostatic Neoplasms, Castration-Resistant | 101 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04597411) |
| April 30, 2018 | NCT03511664 | Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer | Endocyte | Phase 3 | Completed | Prostate Cancer | 861 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03511664) |
| February 3, 2017 | NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy | Endocyte | Phase 2 | Terminated | Metastatic Castration Resistant Prostate Cancer | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03042312) |
| January 5, 2017 | NCT03011320 | An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery | Endocyte | Phase 1 | Completed | Ovary Cancer | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03011320) |
| July 29, 2014 | NCT02202447 | Phase 1 of EC1169 In Patients With Recurrent MCRPC | Endocyte | Phase 1 | Completed | Prostate Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02202447) |
| January 30, 2014 | NCT02049281 | A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011) | Endocyte | Phase 1 | Terminated | Solid Tumor | 3 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02049281) |
| December 3, 2013 | NCT01999738 | Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors | Endocyte | Phase 1 | Completed | Solid Tumors, Non Small Cell Lung Carcinoma | 93 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01999738) |
| October 1, 2013 | NCT01953536 | Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative... | Endocyte | Phase 2 | Withdrawn | Breast Neoplasms | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01953536) |
| December 13, 2012 | NCT01748864 | Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers | Endocyte | Phase 1 | Completed | Healthy | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01748864) |
| September 21, 2012 | NCT01689766 | Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma | Endocyte | Phase 2 | Completed | Metastatic Renal Cell Carcinoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689766) |
| September 21, 2012 | NCT01689727 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors | Endocyte | Phase 2 | Completed | Pituitary Tumors | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689727) |
| September 21, 2012 | NCT01689714 | Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma | Endocyte | Phase 2 | Completed | Ovarian Carcinoma, Recurrent Endometrial Carcinoma | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689714) |
| September 21, 2012 | NCT01689662 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma | Endocyte | Phase 2 | Completed | Metastatic Renal Cell Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689662) |
| September 21, 2012 | NCT01689636 | Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients | Endocyte | Phase 1 | Completed | Ovarian Cancer, Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689636) |
| September 20, 2012 | NCT01688791 | A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001) | Endocyte | Phase 1 | Terminated | Advanced Cancer | 37 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01688791) |
| September 18, 2012 | NCT01686256 | Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer | Endocyte | Phase 1 | Completed | Ovarian Cancer, Endometrial Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01686256) |
| September 12, 2012 | NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid... | Endocyte | Phase 2 | Completed | Recurrent or Metastatic Cancer, Head and Neck Cancer, Pancreas Cancer, Bladder Cancer, Testicular Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01684098) |
| April 16, 2012 | NCT01577654 | Phase 2 Study of EC145 Alone Versus EC145+Docetaxel Versus Docetaxel Alone in Participants With FR(++) 2nd Line Non Small Cell Lung Cancer | Endocyte | Phase 2 | Completed | Non Small Cell Lung Cancer | 203 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01577654) |
| July 27, 2010 | NCT01170650 | Study for Women With Platinum Resistant Ovarian Cancer Evaluating EC145 in Combination With Doxil® (PROCEED) | Endocyte | Phase 3 | Terminated | Ovarian Cancer | 441 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01170650) |
| October 28, 2009 | NCT01002924 | Extension Study of EC145 (Vintafolide) for Subjects Enrolled in a Previous Study With EC145 (MK-8109-010) | Endocyte | Phase 2 | Completed | Solid Tumors | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01002924) |
| February 26, 2009 | NCT00852189 | Study of EC0489 for the Treatment of Refractory or Metastatic Tumors | Endocyte | Phase 1 | Completed | Cancer | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00852189) |
| July 25, 2008 | NCT00722592 | Platinum Resistant Ovarian Cancer Evaluation of Doxil and Vintafolide (MK-8109, EC145) Combination Therapy (8109-009, EC-FV-04) | Endocyte | Phase 2 | Completed | Ovarian Cancer | 162 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00722592) |
| August 6, 2007 | NCT00511485 | Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) | Endocyte | Phase 2 | Completed | Adenocarcinoma of the Lung | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00511485) |
| July 26, 2007 | NCT00507741 | Study of Vintafolide (MK-8109, EC145) in Participants With Advanced Ovarian and Endometrial Cancers (MK-8109-007, EC-FV-02) | Endocyte | Phase 2 | Completed | Ovarian Cancer, Endometrial Cancer | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00507741) |
| June 13, 2007 | NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma | Endocyte | Phase 2 | Terminated | Renal Cell Carcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00485563) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 13 |
| Phase 2 | 13 |
| Phase 3 | 2 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 5 |
| Withdrawn | 1 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 11 |
| Ovarian Neoplasms | 8 |
| Neoplasm Metastasis | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Carcinoma, Renal Cell | 3 |
| Endometrial Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Recurrence | 3 |
| Adenocarcinoma | 3 |
| Breast Neoplasms | 1 |
| Prostatic Neoplasms, Castration-Resistant | 1 |
| Genital Neoplasms, Male | 1 |
| Urogenital Neoplasms | 1 |
| Neoplasms by Site | 1 |
| Genital Diseases, Male | 1 |
| Prostatic Diseases | 1 |
| Carcinoma, Ovarian Epithelial | 1 |
| Pituitary Neoplasms | 1 |
| Adenocarcinoma of Lung | 1 |
| Head and Neck Neoplasms | 1 |
| Pancreatic Neoplasms | 1 |
| Urinary Bladder Neoplasms | 1 |
| Testicular Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Restaurants in the United States](https://specstream.ai/data/businesses/restaurants/united-states)
- [Textile manufacturers in the United States](https://specstream.ai/data/businesses/textile-manufacturers/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Bankruptcy law firms in the United States](https://specstream.ai/data/businesses/bankruptcy-law-firms/united-states)
- [Cocktail bars in the United States](https://specstream.ai/data/businesses/cocktail-bars/united-states)
- [Emergency and urgent care facilities in the United States](https://specstream.ai/data/businesses/emergency-and-urgent-care-facilities/united-states)
